CClinicalTrials.gg
RecruitingNCT05982769Updated Sep 28, 2026

Molecular Mechanism of Exercise in Cirrhosis

An interventional study of Endurance Training 3 times per week and Resistance Exercise in Cirrhosis, Liver, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

This study aims to investigate the effects of 12 weeks of resistance or endurance exercise on patients with cirrhosis. Cirrhotic patients are prone to muscle loss (sarcopenia) and ammonia build up due to liver dysfunction. The liver which in healthy patients is able to process ammonia through ureagenesis is unable to do so in cirrhosis and ammonia is taken up either by the brain causing confusion or the skeletal muscle causing muscle loss or sarcopenia. Primary sarcopenia occurs in older individuals and can be mitigated by exercise. Secondary sarcopenia occurs in response to disease such as cancer, chronic kidney disease, multiple sclerosis, and cirrhosis of all etiologies. Resistance exercise is an excellent stimulator for muscle protein synthesis and is widely used to build muscle mass and strength but has little benefit to cardiovascular function. Endurance exercise has shown to be safe in cirrhosis however there is no set prescription for cirrhosis as there is for other disease. Endurance exercise is known to promote improved cardiovascular health, improve fatigue, and generates less ammonia build up than resistance exercise. In patients with low muscle mass it is possible that endurance exercise alone will be enough to improve muscle mass. There have been few studies on exercise and cirrhosis, those that exist have shown benefits with endurance exercise. However there are even more limited studies on resistance exercise and few to no studies on the molecular mechanisms behind exercise in cirrhosis. Study visits are described fully in the protocol and consent form. After passing a screening visit patients will undergo a maximal exercise/fitness test (pre-baseline test) and other body composition measurements. After the screening and pre-baseline visit randomization will occur (2:2:1 endurance, resistance, or SOC) arrangements will be made to have the appropriate exercise equipment given to patients. Once the exercise equipment has arrived a baseline study visit will occur. After the baseline visit the endurance exercise group will cycle 3 days per week for 60 minutes under the supervision of the study team. The resistance exercise group will perform a whole body resistance workout 2 days per week for approximately 60 minutes under the supervision of a study team member.

Patients in all groups will have the fitness test repeated at weeks 4, 8 and 12. After the 12 weeks of exercise the baseline visits will be repeated and after 2 weeks patients will complete one final fitness test to examine the effects of de-training.

02

Conditions studied

  • Cirrhosis, Liver

Browse trials for

03

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion

  • Adult patients age 21-65 years of both genders
  • Diagnosis of cirrhosis by either liver biopsy, clinical, biochemical or imaging criteria
  • Child's score 5-10
  • Model for End Stage Liver Disease (MELD) score less than 21
  • Abstinence from alcohol and/or other recreational drugs for at least 6 months
  • Absence of concurrent illnesses (renal, cardiac, pulmonary, cerebrovascular, malignancy) or medication (anabolic steroids, corticosteroids) intake that affect skeletal muscle mass, diabetes mellitus (avoid altered muscle protein metabolism), or use of anticoagulants.
  • abdominal or liver CT scan within 1 year of enrollment for stratification Exclusion
  • Active alcohol consumption within 6 weeks of enrollment
  • Pedal edema (grade 2) above the ankle will be excluded to avoid complications of the muscle biopsy.
  • Liver transplant
  • Active Malignancy
  • Recent GI bleed (4 weeks)
  • Hepatic Encephalopathy within previous 6 months
  • Grade 2 or greater active esophageal varices
  • Active infection
  • Large Ascites as defined by clinical imaging
  • Advanced disease cardiac or pulmonary disease
  • Use of medications affecting muscle protein turnover including corticosteroids or medications used to prevent clotting
  • Clinical lab values that indicate potential poor clotting as determined by the PI
  • Inability to obtain informed consent; judged likely to be unable to perform exercise or unlikely to complete the study in the opinion of the investigators
  • End stage kidney disease as determined by glomerular filtration rate (eGFR) \< 15 ml/min/1.73m2 or dialysis
  • Patients who in the opinion of the PI are unsafe for exercise (failure to pass stress test)
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Endurance Arm

    Behavioral: Endurance Training 3 times per week

  • Experimental
    Resistance

    Behavioral: Resistance Exercise

  • Active comparator
    Standard of Care

    Behavioral: Standard of Care

Interventions

  • BehavioralEndurance Training 3 times per week

    endurance training will be performed from home 3 times per week under the supervision of the research team.

  • BehavioralResistance Exercise

    resistance training will be performed from home 2 times per week under the supervision of the research team.

  • BehavioralStandard of Care

    continue usual activity

05

What researchers measure

Primary outcomes

  1. Change in muscle mass over time

    Time frame: day 0 and day 90

06

Study locations

1 of 1 sites recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    • Annette Bellar · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05982769
Lead sponsor
The Cleveland Clinic
Responsible party
Srinivasan Dasarathy (Staff Physician, The Cleveland Clinic) — Principal investigator
First posted
Aug 9, 2023
Start date
Jun 1, 2023
Primary completion
Aug 10, 2027 (estimated)
Completion
Aug 10, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Srinivasan Dasarathy, MD
Contact
dasaras@ccf.org
216-318-7010
Annette Bellar
Contact
bellara@ccf.org

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion